FDA and CDC Officials Announce Temporary Pause on Johnson and Johnson Vaccine
Federal health agencies issue a temporary halt to the Johnson and Johnson COVID-19 vaccine as they investigate rare blood clot cases. Officials urge the public to remain calm and monitor for symptoms while the review takes place.
FDA and CDC officials hold a joint press conference to announce a recommended pause on the Johnson and Johnson COVID-19 vaccine. This immediate precaution follows reports of six rare but severe blood clot cases out of nearly seven million administered doses. The agencies state that this temporary halt allows experts to gather more data and understand the exact nature of these adverse events.
During the briefing, top health officials emphasize that this is exactly how the safety monitoring system works to protect the public. They note that the blood clots, known as cerebral venous sinus thrombosis, occur alongside low platelet levels and require a highly specific treatment that differs from standard blood clot therapies. Doctors receive urgent guidance to avoid using the common blood thinner heparin in these specific situations.
Officials stress that these adverse events appear to be extremely rare and encourage individuals who recently received the Johnson and Johnson vaccine to seek medical care if they experience severe headaches, abdominal pain, leg pain, or shortness of breath within three weeks. They remind the public that other authorized COVID-19 vaccines remain widely available and continue to play a crucial role in ending the pandemic.